Company Performance Metrics
Oxailis develops medical imaging software that applies artificial intelligence to standard 3D ultrasound to quantify tissue perfusion. The company focuses on automated, non-invasive assessment of vascular function using existing ultrasound hardware. Its technology is designed to support diagnostic decision-making across obstetrics, nephrology, and
oncology, including prostate and ovarian cancer. The core software platform processes 3D sonograms to generate reproducible perfusion metrics rather than relying on contrast-enhanced CT or MRI. Clinical teams use these quantitative outputs to investigate disease risk and progression in organs such as the placenta and kidney. Oxailis positions its tools for use at the point of care, integrating into conventional ultrasound workflows to provide additional functional insight alongside structural imaging.
